Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injury; A Randomized Double-Blind Placebo-Controlled Clinical Trial

• Published in: World neurosurgery 2017
• Main Authors: Khalili, Hosseinali, MD, Derakhshan, Nima, MD, Niakan, Amin, MD, Ghaffarpasand, Fariborz, MD, Salehi, Mohammad, MD, Eshraghian, Hamed, MD, Shakibafard, Alireza, MD, Zahabi, Bita, B.Sc
• Format: Article
• Language: English
• Subjects: Neurosurgery
• ISSN: 1878-8750
• DOI: 10.1016/j.wneu.2017.01.103

Abstract Objective The aim of the current study was to investigate the effects of oral glibenclamide on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injury (TBI). Methods This was randomized clinical trial being conducted during a 16-month period from May 2015 and August 2016 in a level I trauma center in Southern Iran. We included 66 patients with moderate (GCS: 9-13) to severe (GCS: 5-8) TBI who had brain contusions of less than 30cc volume. We excluded those who required surgical intervention. Patients were randomly assigned to receive daily 10 mg oral Glibenclamide for 10 days (n=29) or placebo in the same dosage (n=23). The brain contusion volumetry was performed on days 0, 3 and 7 utilizing spiral thin-cut brain CT-Scan (1-mm thickness). The outcome measured included modified Rankin scale (MRS), Glasgow Outcome Scale (GOS) and Disability rating Scale (DRS) which were all evaluated 3 months post-injury. Results There was no significant difference between two study group regarding the baseline, 3rd day and 7th day of the contusion volume. However, those receiving glibenclamide had significantly lower expansion ratio from first to second volumetry ( p